A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib

• Published in: The Korean journal of gastroenterology Vol. 65; no. 6; pp. 366 - 369
• Main Authors: Jang, Bo Hyun, Kim, Byung-Wook, Lim, Keun Joon, Kim, Boo Gyoung, Park, Sung Min, Kim, Joon Sung, Ji, Jeong-Seon, Choi, Hwang
• Format: Journal Article
• Language: English
• Published: Korea (South) 대한소화기학회 01.06.2015
• Subjects: Aged; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Exanthema - etiology; Female; Gastrointestinal Neoplasms - diagnosis; Gastrointestinal Neoplasms - drug therapy; Gastrointestinal Neoplasms - pathology; Gastrointestinal Stromal Tumors - diagnosis; Gastrointestinal Stromal Tumors - drug therapy; Gastrointestinal Stromal Tumors - pathology; Humans; Imatinib Mesylate - adverse effects; Imatinib Mesylate - therapeutic use; Immunohistochemistry; Proto-Oncogene Proteins c-kit - metabolism; Tomography, X-Ray Computed; 내과학; Gastrointestinal stromal tumors; Imatinib
• ISSN: 1598-9992; 2233-6869
• DOI: 10.4166/kjg.2015.65.6.366

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Imatinib mesylate is recommended as adjuvant therapy for GIST after surgical resection. However, drug-related adverse events are common. A 74-year-old female with metastatic GIST who was managed with imatinib experienced severe adverse events, including skin rashes, tremor, and alopecia, etc. The imatinib dose was reduced and the size of the metastatic GIST continued to decrease and adverse events showed significant improvement.